BlueCrest Capital Management Ltd Invests $527,000 in Boston Scientific Co. (NYSE:BSX)

BlueCrest Capital Management Ltd purchased a new position in shares of Boston Scientific Co. (NYSE:BSX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,259 shares of the medical equipment provider’s stock, valued at approximately $527,000.

Several other institutional investors have also bought and sold shares of the business. MANA Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $3,154,000. Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of Boston Scientific by 2,186.1% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 505,826 shares of the medical equipment provider’s stock worth $12,539,000 after buying an additional 483,700 shares in the last quarter. Truewealth LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $116,000. AXA lifted its holdings in shares of Boston Scientific by 1.4% in the 4th quarter. AXA now owns 1,249,787 shares of the medical equipment provider’s stock worth $30,982,000 after purchasing an additional 17,475 shares in the last quarter. Finally, Delpha Capital Management LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $135,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, CFO Daniel J. Brennan sold 60,209 shares of Boston Scientific stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $27.87, for a total value of $1,678,024.83. Following the completion of the sale, the chief financial officer now owns 299,644 shares of the company’s stock, valued at approximately $8,351,078.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP John Bradley Sorenson sold 1,950 shares of Boston Scientific stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $27.43, for a total value of $53,488.50. The disclosure for this sale can be found here. In the last three months, insiders sold 252,818 shares of company stock valued at $6,879,888. 0.74% of the stock is currently owned by insiders.

Shares of Boston Scientific stock traded down $0.74 during trading hours on Friday, hitting $27.35. 6,451,369 shares of the company’s stock traded hands, compared to its average volume of 6,659,507. Boston Scientific Co. has a 12-month low of $24.31 and a 12-month high of $29.93. The firm has a market cap of $37,603.82, a PE ratio of 21.71, a P/E/G ratio of 1.98 and a beta of 0.81. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.68 and a quick ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same period last year, the firm posted $0.30 EPS. The business’s revenue was up 9.9% compared to the same quarter last year. equities analysts anticipate that Boston Scientific Co. will post 1.37 EPS for the current fiscal year.

A number of equities analysts recently issued reports on BSX shares. Royal Bank of Canada reiterated a “top pick” rating and issued a $32.00 target price on shares of Boston Scientific in a report on Monday, March 5th. TheStreet upgraded Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 target price on shares of Boston Scientific in a report on Tuesday, March 27th. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, ValuEngine cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Boston Scientific presently has an average rating of “Buy” and a consensus price target of $31.45.

WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/bluecrest-capital-management-ltd-takes-position-in-boston-scientific-co-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply